CN108929287A - 沃替西汀的精制 - Google Patents
沃替西汀的精制 Download PDFInfo
- Publication number
- CN108929287A CN108929287A CN201710382294.2A CN201710382294A CN108929287A CN 108929287 A CN108929287 A CN 108929287A CN 201710382294 A CN201710382294 A CN 201710382294A CN 108929287 A CN108929287 A CN 108929287A
- Authority
- CN
- China
- Prior art keywords
- vortioxetine
- solvent
- toluene
- reflux
- crystallization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种抗抑郁药物氢溴酸沃替西汀的精制方法:在混合溶剂的体系中重结晶,得到类白色晶体,该方法的收率高,且终产品达到医药级别。
Description
技术领域
本发明属于医药技术领域,具体涉及抗抑郁药物沃替西汀氢溴酸酸盐精制方法的研究。
背景技术
沃替西汀 (vortioxetine),化学名1-[2-(2,4-二甲基苯基硫基)苯基]哌嗪氢溴酸盐,适用于重度抑郁症的治疗,2013年9月美国食品药品监督管理局(FDA)批准其上市,商品名为Latuda,其分子式如下:
。
药物精制的研究是新药研发、工艺设计以及药物剂型设计过程中非常重要的组成部分。对于药物研发工作者根据生物利用度及稳定性在设计原料药及制剂的制备工艺时具有极大的帮助。同时也保证了药物的质量,为患者的安全用药提供了有力的保障。
发明内容
本发明公开了一种抗抑郁药物沃替西汀(化学式如下)的精制方法:在混合溶剂的体系中重结晶,得到类白色晶体,该方法的收率高,且可是终产品达到医药级别。
具体操作如下:将样品置于甲苯与异丙醇为溶剂的体系中,加热回流,冷却析晶后的到产物。
具体操作如下:先以甲苯为溶剂成氢溴酸盐,得到的氢溴酸盐在异丙醇、乙腈、甲苯、乙酸乙酯、丙酮一种或两种的混合溶剂的体系中加热回流,冷却析晶,得到沃替西汀;其中,溶剂:原料药=5:1-50:1。
具体实施实例
以下结合实例对本发明进行更详细的描述,但不作为对本发明的限制。
实施例1
向单口瓶(100 mL)中加入异丙醇与甲苯(比例=1:5,AR,50 mL)和沃替西汀氢溴酸盐(5g),加热使其回流,回流一小时,降温,冷却析晶;析晶2h后抽滤,滤饼干燥16h,即得到沃替西汀,收率92.5%,纯度99.83%。
实施例2
向三口瓶(100)ml中加入异丙醇与乙酸乙酯(比例=1:30,AR,,50mL)和沃替西汀氢溴酸盐(5g),加热回流,回流1h,降温,冷却析晶;析晶2h后抽滤,滤饼干燥16h,即得到沃替西汀,收率93.2%,纯度99.86%。
实施例3
向三口瓶(100)ml中加入异丙醇与乙腈(比例=1:50,AR,,50mL)和沃替西汀氢溴酸盐(5g),加热回流,回流1h,降温,冷却析晶;析晶2h后抽滤,滤饼干燥16h,即得到沃替西汀,收率92.5%,纯度99.90%。
实施例4
向三口瓶(100)ml中加入丙酮与乙腈(比例=1:15,AR,,50mL)和沃替西汀氢溴酸盐(5g),加热回流,回流1h,降温,冷却析晶;析晶2h后抽滤,滤饼干燥16h,即得到沃替西汀,收率90.5%,纯度99.78%。
Claims (3)
1.抗抑郁药物沃替西汀的精制方法,在混合溶剂的体系中重结晶,得到晶体为类白色晶体。
2.根据权利要求1所述的沃替西汀的精制方法,先以甲苯为溶剂成氢溴酸盐,得到的氢溴酸盐在异丙醇、乙腈、甲苯、乙酸乙酯、丙酮为溶剂的体系中加热回流,进而冷却析晶,得到沃替西汀。
3.根据权利要求1所述的沃替西汀精制过程,溶剂:原料药=5:1-50:1。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710382294.2A CN108929287A (zh) | 2017-05-26 | 2017-05-26 | 沃替西汀的精制 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710382294.2A CN108929287A (zh) | 2017-05-26 | 2017-05-26 | 沃替西汀的精制 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108929287A true CN108929287A (zh) | 2018-12-04 |
Family
ID=64451047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710382294.2A Pending CN108929287A (zh) | 2017-05-26 | 2017-05-26 | 沃替西汀的精制 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108929287A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104119298A (zh) * | 2014-08-13 | 2014-10-29 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
WO2016079751A2 (en) * | 2014-11-17 | 2016-05-26 | Megafine Pharma (P) Ltd. | A process for preparation of vortioxetine and polymorphs thereof |
CN106279065A (zh) * | 2015-05-12 | 2017-01-04 | 北京深蓝海生物医药科技有限公司 | 一种氢溴酸沃替西汀的精制转晶方法 |
-
2017
- 2017-05-26 CN CN201710382294.2A patent/CN108929287A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104119298A (zh) * | 2014-08-13 | 2014-10-29 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
WO2016079751A2 (en) * | 2014-11-17 | 2016-05-26 | Megafine Pharma (P) Ltd. | A process for preparation of vortioxetine and polymorphs thereof |
CN106279065A (zh) * | 2015-05-12 | 2017-01-04 | 北京深蓝海生物医药科技有限公司 | 一种氢溴酸沃替西汀的精制转晶方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11524937B2 (en) | Indirubin derivatives, and uses thereof | |
CN111094242A (zh) | 用于治疗与nlrp活性相关的病症的化合物和组合物 | |
MX2015002695A (es) | Derivados biciclicos fusionados de sulfamoilo y su uso como medicamentos para el tratamiento de la hepatitis b. | |
AU2015374763B2 (en) | Method for preparing Sofosbuvir crystal form-6 | |
JP2016537346A5 (zh) | ||
CN109503517A (zh) | 一种沃替西汀α晶型的制备方法 | |
CN108929287A (zh) | 沃替西汀的精制 | |
CN106316986A (zh) | 一种1-[2-(2,4-二甲基苯基硫烷基)苯基]哌嗪氢溴酸盐α型晶体的制备方法 | |
CN104364248A (zh) | 甲磺酸氟马替尼晶型及其制备方法和用途 | |
CN107915678A (zh) | 一种用于治疗特发性血小板减少性紫癜的药物艾曲波帕的制备方法 | |
ES2727667T3 (es) | Polimorfos de lenalidomida | |
CN105440014A (zh) | 一种来那度胺的制备方法 | |
CN103360326A (zh) | 吉非替尼晶型i的精制方法 | |
CN105348069A (zh) | 一种格列本脲中间体5-氯水杨酸的合成工艺 | |
CN107011289A (zh) | 沃替西汀β晶型的制备方法 | |
CN106905298A (zh) | 盐酸尼洛替尼杂质的制备方法 | |
CN106543102A (zh) | 1,5‑苯并硫氮杂卓类衍生物及其应用 | |
CN105254590B (zh) | 沃替西汀氢溴酸盐晶型及其制备方法和用途 | |
CN106478603B (zh) | 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途 | |
CN105315196A (zh) | 一种高纯度盐酸左布比卡因精制方法 | |
CN105777714B (zh) | 氟马替尼的精制方法 | |
CN104230984B (zh) | 一种三水合3‑氨基丙基胺乙基硫代磷酸的制备方法 | |
CN107311973B (zh) | 一种含硝酸酯基二氢杨梅素衍生物及其制备和应用 | |
CN104529914B (zh) | 4,4′‑羰基二‑1‑乙基哌嗪‑2,3‑二酮的合成方法 | |
CN102512421B (zh) | 哌嗪酰胺类化合物在制药中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181204 |
|
WD01 | Invention patent application deemed withdrawn after publication |